Cardiac effects of antimalarial treatment with halofantrine

F. Nosten; Feiko Ter Kuile; C. Luxemburger; C. Woodrow; T. Chongsuphajaisiddhi; N. J. White; D. E. Kyle

doi:10.1016/0140-6736(93)92412-m

Cardiac effects of antimalarial treatment with halofantrine

F. Nosten, Feiko Ter Kuile, C. Luxemburger, C. Woodrow, T. Chongsuphajaisiddhi, N. J. White, D. E. Kyle

Research output: Contribution to journal › Article › peer-review

271 Citations (Scopus)

Abstract

In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n=53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0·55 s1/2 or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2·0 [95% Cl 1·1-3·4], p = 0·04). More than 60% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated.

Original language	English
Pages (from-to)	1054-1056
Number of pages	3
Journal	The Lancet
Volume	341
Issue number	8852
DOIs	https://doi.org/10.1016/0140-6736(93)92412-m
Publication status	Published - 24 Apr 1993
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0140-6736(93)92412-m

Cite this

@article{dcf2217169ec43dca464f705e119592d,

title = "Cardiac effects of antimalarial treatment with halofantrine",

abstract = "In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n=53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25\% or a QTc of 0·55 s1/2 or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2·0 [95\% Cl 1·1-3·4], p = 0·04). More than 60\% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated.",

author = "F. Nosten and \{Ter Kuile\}, Feiko and C. Luxemburger and C. Woodrow and T. Chongsuphajaisiddhi and White, \{N. J.\} and Kyle, \{D. E.\}",

year = "1993",

month = apr,

day = "24",

doi = "10.1016/0140-6736(93)92412-m",

language = "English",

volume = "341",

pages = "1054--1056",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8852",

}

TY - JOUR

T1 - Cardiac effects of antimalarial treatment with halofantrine

AU - Nosten, F.

AU - Ter Kuile, Feiko

AU - Luxemburger, C.

AU - Woodrow, C.

AU - Chongsuphajaisiddhi, T.

AU - White, N. J.

AU - Kyle, D. E.

PY - 1993/4/24

Y1 - 1993/4/24

N2 - In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n=53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0·55 s1/2 or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2·0 [95% Cl 1·1-3·4], p = 0·04). More than 60% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated.

AB - In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n=53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0·55 s1/2 or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2·0 [95% Cl 1·1-3·4], p = 0·04). More than 60% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated.

U2 - 10.1016/0140-6736(93)92412-m

DO - 10.1016/0140-6736(93)92412-m

M3 - Article

SN - 0140-6736

VL - 341

SP - 1054

EP - 1056

JO - The Lancet

JF - The Lancet

IS - 8852

ER -

Cardiac effects of antimalarial treatment with halofantrine

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this